Hangzhou Neoantigen Therapeutics

Hangzhou Neoantigen Therapeutics develops personalized cancer immunotherapies based on tumor neoantigens using advanced AI-driven platforms. Their lead product P01—a personalized therapeutic peptide vaccine—was the first such drug to enter clinical trials in China and has shown safety/efficacy signals in early studies (~80 patients). The company also develops mRNA-based vaccines like iNeo-Vac-R01 currently in Phase I trials targeting multiple solid tumor types including metastatic hepatocellular carcinoma. They have established China's largest clinical database of neoantigen vaccines through extensive IITs since at least 2017.